Amylyx Pharmaceuticals (AMLX) CEO share sale covers tax obligations

Rhea-AI Filing Summary

Amylyx Pharmaceuticals director and Co-CEO Joshua B. Cohen reported an automatic tax-related share sale. On March 2, 2026, 29,282 shares of common stock were sold at a weighted average price of $14.484 per share to cover tax withholding owed on vesting restricted stock units.

The filing notes these sales were required to satisfy withholding obligations and were not made at Cohen’s discretion. After the transaction, he continues to directly own 3,334,683 shares of Amylyx common stock, indicating he retains a substantial equity stake in the company.

Insider Trade Summary

Net Seller: 29,282 shares ($424,120)

Net Sell 1 txn

Insider Cohen Joshua B

Role Co-Chief Executive Officer

Sold 29,282 shs ($424K)

Type	Security	Shares	Price	Value
Sale	Common Stock	29,282	$14.484	$424K

Holdings After Transaction: Common Stock — 3,334,683 shares (Direct)

Footnotes (1)

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.450 to $15.160. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Joshua B

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		29,282(1)	D	$14.484(2)	3,334,683	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.450 to $15.160. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

	/s/ Joshua B. Cohen	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Amylyx Pharmaceuticals (AMLX) report for Joshua B. Cohen?

Amylyx Pharmaceuticals reported that Co-CEO Joshua B. Cohen sold 29,282 shares of common stock. The shares were sold on March 2, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units, according to the Form 4 footnotes.

How many Amylyx (AMLX) shares did Joshua B. Cohen sell and at what price?

Joshua B. Cohen sold 29,282 Amylyx common shares at a weighted average price of $14.484. The shares were sold in multiple transactions within a price range from $14.450 to $15.160 per share, as disclosed in the Form 4 filing footnotes.

Why did Amylyx Co-CEO Joshua B. Cohen sell shares according to the Form 4?

The Form 4 states Cohen’s sale was to cover tax withholding obligations tied to vesting restricted stock units. The footnote explains the sales were automatic for tax purposes and were not executed at Cohen’s personal discretion in the open market.

How many Amylyx (AMLX) shares does Joshua B. Cohen still own after this transaction?

After the reported tax-related sale, Joshua B. Cohen directly owns 3,334,683 shares of Amylyx common stock. This post-transaction balance is disclosed in the Form 4 and shows he continues to maintain a significant direct ownership position in the company.

Were Joshua B. Cohen’s Amylyx share sales discretionary open-market trades?

No, the footnotes explain the sales were automatic to cover tax withholding from restricted stock unit vesting. Although coded as open-market sales, the filing specifies they were required for taxes and not executed at Cohen’s discretion as ordinary portfolio trades.

What price range did Amylyx (AMLX) shares sell for in Cohen’s March 2, 2026 transaction?

The filing reports a weighted average sale price of $14.484 per share. Footnotes clarify the individual trades occurred at prices ranging from $14.450 to $15.160, and detailed breakdowns can be provided to SEC staff upon request.